Remove 2023 Remove Atrial Fibrillation Remove Risk Factors
article thumbnail

Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat Atrial Fibrillation

DAIC

About Atrial Fibrillation and Pulsed Field Ablation AF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide3. 4-7 Current ablation technologies rely on thermal effects to target cardiac tissue and risk damage to additional collateral structures in the heart.

article thumbnail

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Circulation

Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. In Europe, the TRUPULSE generator received CE mark in late 2023 and the VARIPULSE Catheter received CE mark in February 2024. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. In the U.S.,

article thumbnail

Systemic immune–inflammation index for predicting postoperative atrial fibrillation following cardiac surgery: a meta-analysis

Frontiers in Cardiovascular Medicine

Background Postoperative atrial fibrillation (POAF) is a frequent complication that may increase morbidity and mortality risk following cardiac surgery. Recent studies have reported associations between elevated SII and increased POAF risk; however, significant heterogeneity exists regarding its predictive efficacy.

article thumbnail

Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC

DAIC

Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. tim.hodson Fri, 01/24/2025 - 11:03 Jan. 22, 2025 Anthos Therapeutics, Inc.,

AFIB 52
article thumbnail

Increased Risk of Heart Rhythm Disruption After COVID-19

DAIC

Ioannis Katsoularis, image courtesy of Klas Sjöberg milla1cf Thu, 12/14/2023 - 09:23 December 14, 2023 — Individuals infected with COVID-19 are also at an increased risk of suffering from heart rhythm disturbances, such as atrial fibrillation.

COVID-19 111
article thumbnail

PO-04-046 UNVEILING THE HIDDEN STROKE THREAT IN PATIENTS WITH ATRIAL FIBRILLATION AND PRIMARY HYPERPARATHYROIDISM

HeartRhythm

2023 ACC/AHA/ACCP/HRS guidelines suggest that patients with Atrial fibrillation (AF) at intermediate to low annual risk of ischemic stroke can benefit from consideration of factors that might modify their risk of stroke.